Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Why EU Must Reform Regulation And Funding For Life-Saving Cancer Biomarker Tests

Executive Summary

UK and EU patients have inadequate and inconsistent access to cancer biomarker tests, which experts warn is hindering the use of life-saving targeted medicines. Could parallel regulatory and reimbursement processes for drugs and diagnostics provide a solution?

You may also be interested in...



EU IVDR Milestone: Cancer Biomarker Test First To Get A Companion Diagnostic CE Marking

A major milestone has been reached in the EU after a cancer biomarker assay became the first product to receive a companion diagnostic certificate in the context of the EU In Vitro Diagnostic Regulation.

UK Has ‘Much Room For Improvement’ On Genomic Testing Access

UK patient outcomes would improve under clearer, standardized market access or reimbursement pathways for advanced diagnostic tests, such as those used to screen for cancer, trade groups say.

EU Taps Power Of AI To Beat Cancer In New Imaging Initiative

The European Commission’s newly-launched Cancer Imaging Initiative will see sophisticated digital technologies based on artificial intelligence used to speed up medical innovations as part of its wider Beating Cancer Plan.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT147394

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel